Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. Issue 1 (10th January 2020)

• Record Type: Journal Article
• Authors: McCutcheon, Robert A.; Krystal, John H.; Howes, Oliver D.
• Is Part Of: World psychiatry. Volume 19:Issue 1(2020)
• Page Start: 15
• Page End: 33
• Publication Date: 2020-01-10
• Subjects: Psychosis -- schizophrenia -- dopamine -- glutamate -- antipsychotics -- striatum -- NMDA receptors -- D2 receptors -- D1 receptors -- dorsolateral prefrontal cortex -- GABA interneurons -- amphetamine -- ketamine -- cognitive symptoms; Psychiatry -- Periodicals; Mental illness -- Periodicals; 616.89005
• DOI: 10.1002/wps.20693
• Languages: English
• ISSNs: 1723-8617

Abstract

Abstract : Glutamate and dopamine systems play distinct roles in terms of neuronal signalling, yet both have been proposed to contribute significantly to the pathophysiology of schizophrenia. In this paper we assess research that has implicated both systems in the aetiology of this disorder. We examine evidence from post‐mortem, preclinical, pharmacological and in vivo neuroimaging studies. Pharmacological and preclinical studies implicate both systems, and in vivo imaging of the dopamine system has consistently identified elevated striatal dopamine synthesis and release capacity in schizophrenia. Imaging of the glutamate system and other aspects of research on the dopamine system have produced less consistent findings, potentially due to methodological limitations and the heterogeneity of the disorder. Converging evidence indicates that genetic and environmental risk factors for schizophrenia underlie disruption of glutamatergic and dopaminergic function. However, while genetic influences may directly underlie glutamatergic dysfunction, few genetic risk variants directly implicate the dopamine system, indicating that aberrant dopamine signalling is likely to be predominantly due to other factors. We discuss the neural circuits through which the two systems interact, and how their disruption may cause psychotic symptoms. We also discuss mechanisms through which existing treatments operate, and how recent research has highlighted opportunities for the development of novel pharmacological therapies. Finally, we consider outstanding questions for the field, including what remains unknown regarding the nature of glutamate and dopamine function in schizophrenia, and what needs to be achieved to make progress in developing new treatments.